2009 Executive Compensation Table for ARYx Therapeutics, Inc. Named Officers
This document lists the 2009 annual base salaries and target cash incentive percentages for the named executive officers of ARYx Therapeutics, Inc. It details the compensation structure for each officer, including their base salary and the percentage of that salary eligible as a performance-based cash incentive for the year. The agreement outlines the company's compensation plan for its top executives for 2009.
EXHIBIT 10.20
COMPENSATION INFORMATION FOR NAMED EXECUTIVE OFFICERS
The table below provides information regarding the 2009 annual base salary and target percentage for a cash incentive payment for performance in 2009, of each named executive officer of ARYx Therapeutics, Inc.
|
|
|
|
| 2009 Target Cash |
| |
|
|
|
|
| Incentive Payment |
| |
|
|
|
|
| (As% |
| |
|
|
| 2009 Annual Base |
| of 2009 Annual |
| |
| Name and Principal Position |
| Salary |
| Base Salary) |
| |
| Paul Goddard, Ph.D. |
|
|
|
|
| |
| Chairman and Chief Executive Officer |
| $ | 451,000 |
| 75.0 | % |
| Peter G. Milner, M.D. |
|
|
|
|
| |
| President, Research and Development |
| $ | 333,000 |
| 52.5 | % |
| John Varian |
|
|
|
|
| |
| Chief Operating Officer and Chief Financial Officer |
| $ | 324,000 |
| 52.5 | % |
| Pascal Druzgala, Ph.D. |
|
|
|
|
| |
| Vice President and Chief Scientific Officer |
| $ | 283,000 |
| 45.0 | % |
| Daniel Canafax, Pharm.D. |
|
|
|
|
| |
| Vice President and Chief Development Officer |
| $ | 270,000 |
| 45.0 | % |
| David Nagler |
|
|
|
|
| |
| Vice President, Corporate Affairs and Secretary |
| $ | 256,000 |
| 45.0 | % |
